Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Authors:
- A J LeesALA J Lees
- V RatziuVRV Ratziu
- E TolosaETE Tolosa
- W H OertelWOW H Oertel
- 1 September 2007
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 78 (9) , 944-948
Abstract
The safety and tolerability of adjunctive tolcapone initiated simultaneously with levodopa was evaluated with a focus on increases in liver transaminase and hepatotoxicity. 677 levodopa-naïve patients with early stage Parkinson's disease (PD) were randomised to receive placebo or tolcapone 100 mg three times daily, added to standard doses of levodopa plus carbidopa or benserazide. Increases in liver transaminase above the upper limit of normal (ULN) occurred in 69/342 (20.2%) and 92/335 (27.5%) patients in the placebo and tolcapone groups, respectively. Increases > or = 3 times the ULN occurred in 4/342 (1.2%) and 6/335 (1.8%) patients receiving placebo and tolcapone, respectively (p = 0.5). Liver transaminase values returned to normal in 65% of placebo and 80% of tolcapone treated patients. No instances of serious hepatotoxicity were seen. Diarrhoea was the most commonly reported AE-36/342 (11.0%) placebo v 98/335 (29.0%) tolcapone-and caused discontinuation in 9.9% of tolcapone treated patients. Overall, study discontinuation due to adverse effects was 2.9% in the placebo group and 17.3% in the tolcapone group. Tolcapone seemed to be safe and was generally well tolerated as an adjunctive treatment in patients starting treatment with carbidopa/levodopa for symptomatic PD. Mild increases in transaminase levels--< 3 times the ULN--occurred commonly in both placebo and tolcapone treated patients, whereas potentially serious increases of up to > or = 3 times the ULN were infrequent.Keywords
This publication has 16 references indexed in Scilit:
- Are patients with elevated liver tests at increased risk of drug-induced liver injury?Gastroenterology, 2004
- Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's diseaseMovement Disorders, 2002
- Tolcapone and Hepatotoxic EffectsArchives of Neurology, 2000
- Tolcapone and fulminant hepatitisThe Lancet, 1998
- Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-CarbidopaArchives of Neurology, 1998
- Tolcapone added to levodopa in stable parkinsonian patients: A double‐blind placebo‐controlled studyMovement Disorders, 1997
- Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patientsJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatmentNeurology, 1997
- Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor FluctuationsNeurology, 1997
- A Clinicopathologic Study of 100 Cases of Parkinson's DiseaseArchives of Neurology, 1993